EA201890196A1 - Композиция для устранения заложенности носа, обладающая противовирусным действием - Google Patents

Композиция для устранения заложенности носа, обладающая противовирусным действием

Info

Publication number
EA201890196A1
EA201890196A1 EA201890196A EA201890196A EA201890196A1 EA 201890196 A1 EA201890196 A1 EA 201890196A1 EA 201890196 A EA201890196 A EA 201890196A EA 201890196 A EA201890196 A EA 201890196A EA 201890196 A1 EA201890196 A1 EA 201890196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
osmolality
regulating
owned
nose
Prior art date
Application number
EA201890196A
Other languages
English (en)
Other versions
EA037085B1 (ru
Inventor
Андреас Грассауэр
Ева Пришл-Грассауэр
Анжелика Бодентайк
Кристиан Коллер
Мартина Морокутти-Курц
Original Assignee
Мариномед Биотек Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мариномед Биотек Аг filed Critical Мариномед Биотек Аг
Publication of EA201890196A1 publication Critical patent/EA201890196A1/ru
Publication of EA037085B1 publication Critical patent/EA037085B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции для устранения заложенности носа, характеризующейся тем, что указанная композиция содержит гиперосмолярный водный раствор неионного регулирующего осмоляльность агента, необязательно в сочетании с ионным агентом, регулирующим осмоляльность, причем указанная композиция дополнительно содержит йота-каррагинан и/или каппа-каррагинан в качестве активного противовирусного ингредиента в противовирусно эффективном количестве, при условии, что композиция в виде готового к применению состава содержит не более 0-1,5% мас./об. указанного ионного агента, регулирующего осмоляльность. Предложенная композиция подходит для устранения заложенности носа и для профилактического или терапевтического вмешательства при ряде вирусных инфекций верхних дыхательных путей.
EA201890196A 2015-07-14 2016-07-12 Композиция для устранения заложенности носа, обладающая противовирусным действием EA037085B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15176670 2015-07-14
PCT/EP2016/066565 WO2017009351A1 (en) 2015-07-14 2016-07-12 Stuffy nose deblocking composition having antiviral activity

Publications (2)

Publication Number Publication Date
EA201890196A1 true EA201890196A1 (ru) 2018-06-29
EA037085B1 EA037085B1 (ru) 2021-02-04

Family

ID=53717900

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890196A EA037085B1 (ru) 2015-07-14 2016-07-12 Композиция для устранения заложенности носа, обладающая противовирусным действием

Country Status (27)

Country Link
US (1) US10660914B2 (ru)
EP (1) EP3370692B1 (ru)
JP (1) JP6774435B2 (ru)
KR (1) KR102628781B1 (ru)
CN (1) CN107847430B (ru)
AU (1) AU2016293004B2 (ru)
BR (1) BR112018000592B1 (ru)
CA (1) CA2992352C (ru)
CL (1) CL2018000033A1 (ru)
DK (1) DK3370692T3 (ru)
EA (1) EA037085B1 (ru)
ES (1) ES2949139T3 (ru)
FI (1) FI3370692T3 (ru)
HK (1) HK1253038A1 (ru)
HU (1) HUE062108T2 (ru)
IL (1) IL256883B (ru)
LT (1) LT3370692T (ru)
MA (1) MA43155A (ru)
MX (1) MX2018000285A (ru)
MY (1) MY194870A (ru)
NZ (1) NZ738597A (ru)
PH (1) PH12018500044A1 (ru)
PL (1) PL3370692T3 (ru)
PT (1) PT3370692T (ru)
SA (1) SA518390689B1 (ru)
WO (1) WO2017009351A1 (ru)
ZA (1) ZA201708595B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505538A (ja) * 2016-02-17 2019-02-28 エント テクノロジーズ ピーティーワイ リミテッド 副鼻腔疾患および障害の治療のための組成物と方法
GB2567285A (en) * 2017-08-07 2019-04-10 Suprapharm Cc Preparation for nasal-nasopharyngeal treatment
EP4117683A4 (en) 2020-03-12 2024-04-24 Cullis Hill Sydney David TREATMENT OF CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
EP3939597A1 (en) * 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
FR3113237B1 (fr) 2020-08-04 2023-06-09 Biopass Produit pour le traitement de maladies virales par voie nasale
CA3188053A1 (fr) 2020-08-04 2022-02-10 Stephanie Audran Hydrogel comprenant du glycerol et un carbomere pour le traitement par voie nasale des symptomes respiratoires de la maladie covid-19
EP3991561A1 (en) * 2020-10-28 2022-05-04 Vepidan ApS Antimicrobial disinfectant gel
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
KR20230094472A (ko) * 2021-12-21 2023-06-28 (주)메디코어 비강 세정제 조성물 및 그 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
SI2486942T1 (sl) * 2004-11-24 2019-03-29 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki za njihovo uporabo
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition
PT2101792E (pt) 2006-12-05 2010-06-25 Marinomed Biotechnologie Gmbh Utilização de carragenina para tratamento de infecções por rinovírus
US20110059919A1 (en) * 2007-08-24 2011-03-10 Marinomed Biotechnologie Gmbh Antiviral composition comprising a sulfated polysaccharide
FR2926218B1 (fr) * 2008-01-10 2010-08-13 Galderma Res & Dev Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2013049538A1 (en) * 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. Allergen nasal compositions

Also Published As

Publication number Publication date
JP6774435B2 (ja) 2020-10-21
AU2016293004A1 (en) 2018-01-18
WO2017009351A1 (en) 2017-01-19
SA518390689B1 (ar) 2021-07-17
KR20180054570A (ko) 2018-05-24
PT3370692T (pt) 2023-07-18
NZ738597A (en) 2021-12-24
CN107847430B (zh) 2021-02-02
PH12018500044A1 (en) 2018-07-23
DK3370692T3 (da) 2023-06-26
MY194870A (en) 2022-12-21
US20190060358A1 (en) 2019-02-28
HUE062108T2 (hu) 2023-09-28
IL256883A (en) 2018-03-29
FI3370692T3 (fi) 2023-06-16
EP3370692A1 (en) 2018-09-12
PL3370692T3 (pl) 2023-08-14
US10660914B2 (en) 2020-05-26
CA2992352C (en) 2023-06-27
KR102628781B1 (ko) 2024-01-24
ZA201708595B (en) 2021-06-30
CA2992352A1 (en) 2017-01-19
HK1253038A1 (zh) 2019-06-06
BR112018000592A2 (pt) 2018-09-11
MA43155A (fr) 2018-09-12
EA037085B1 (ru) 2021-02-04
AU2016293004B2 (en) 2021-05-06
CN107847430A (zh) 2018-03-27
ES2949139T3 (es) 2023-09-25
CL2018000033A1 (es) 2018-08-10
BR112018000592B1 (pt) 2024-02-06
JP2018523635A (ja) 2018-08-23
MX2018000285A (es) 2018-02-19
EP3370692B1 (en) 2023-04-12
LT3370692T (lt) 2023-07-10
IL256883B (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EA201890196A1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
GB2544439A (en) Antiviral composition
RU2014117294A (ru) 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрат для лечения герпетической инфекции, фармацевтическая композиция для местного применения
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
PH12017501505A1 (en) Respiratory infection treating agent
ITUA20164387A1 (it) Composizione farmaceutica comprendente Cetraria islandica Ach., sodio ialuronato e una soluzione salina per il trattamento di affezioni dell'apparato respiratorio.
EA201501173A1 (ru) Применение адсорбированного гомогената трутневого расплода и витаминов группы d и/или их активных метаболитов для профилактики и лечения острых респираторных заболеваний и гриппа
MX2016009475A (es) Composiciones efectivas contra la conjuntivitis viral.
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
GT201600072A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
TH1801000046A (th) องค์ประกอบที่ใช้สลายจมูกตันที่มีการออกฤทธิ์ต้านไวรัส
MX2020001356A (es) Composiciones farmaceuticas.
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
TH180790A (th) องค์ประกอบที่ประกอบด้วยสารสำหรับการควบคุมการแสดงออกของ abh แอนติเจน